Preclinical data from the TRINITI-1 (NCT02732119) (Study Details Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Here, ERBB2 is linked to breast carcinoma.